{
  "source": "PA-Med-Nec-Vijoice.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2279-4\nProgram Prior Authorization/Medical Necessity\nMedication Vijoice® (alpelisib)\nP&T Approval Date 6/2022, 6/2023, 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nVijoice® (alpelisib) is a kinase inhibitor indicated for the treatment of adult and pediatric patients\n2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum\n(PROS) who require systemic therapy. This indication is approved under accelerated approval\nbased on response rate and duration of response. Continued approval for this indication may be\ncontingent upon verification and description of clinical benefit in a confirmatory trial(s).\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Vijoice will be approved based on ALL of the following criteria:\na. Diagnosis of PIK3CA-Related Overgrowth Spectrum (PROS)\n-AND-\nb. One of the following criteria:\n(1) Confirmed presence of a mutation in the PIK3CA gene\n-OR-\n(2) One of the following:\n(a) Two or more of the following spectrum features:\ni. Overgrowth: adipose, muscle, nerve, skeletal\nii. Vascular malformations: capillary, venous, arteriovenous, lymphatic\niii. Epidermal nevus\n-OR-\n(b) One or more of the following isolated features:\ni. Large isolated lymphatic malformation\nii. Isolated macrodactyly or overgrown splayed feet/ hands with overgrown\nlimbs\niii. Truncal adipose overgrowth\niv. Hemimegalencephaly (bilateral) / dysplastic megalencephaly / focal\ncortical dysplasia\nv. Epidermal nevus\n© 2025 UnitedHealthcare Services Inc.\n1\nvi. Seborrheic keratoses\nvii. Benign lichenoid keratoses\n-AND-\nc. Patient is 2 years of age or older\n-AND-\nd. Patient has severe manifestations of PROS requiring systemic therapy\n-AND-\ne. Prescribed by, or in consultation with, a clinical geneticist or a practitioner who has\nspecialized expertise in the management of PROS manifestations\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Vijoice will be appro",
    ", a clinical geneticist or a practitioner who has\nspecialized expertise in the management of PROS manifestations\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Vijoice will be approved based on both of the following criteria:\na. Documentation of positive clinical response to Vijoice therapy\n-AND-\nb. Prescribed by, or in consultation with, a clinical geneticist or a practitioner who has\nspecialized expertise in the management of PROS manifestations\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Vijoice [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2024.\n2. Keppler-Noreuil, K. M., Rios, J. J., Parker, V. E., Semple, R. K., Lindhurst, M. J., Sapp, J. C.,\nAlomari, A., Ezaki, M., Dobyns, W., & Biesecker, L. G. (2015). PIK3CA-related overgrowth\nspectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.\n© 2025 UnitedHealthcare Services Inc.\n2\nAmerican journal of medical genetics. Part A, 167A(2), 287–295.\nhttps://doi.org/10.1002/ajmg.a.36836\n3. Venot, Q., Blanc, T., Rabia, S. H., Berteloot, L., Ladraa, S., Duong, J. P., Blanc, E., Johnson, S.\nC., Hoguin, C., Boccara, O., Sarnacki, S., Boddaert, N., Pannier, S., Martinez, F., Magassa, S.,\nYamaguchi, J., Knebelmann, B., Merville, P., Grenier, N., Joly, D., … Canaud, G. (2018).\nTargeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature, 558(7711),\n540–5",
    "F., Magassa, S.,\nYamaguchi, J., Knebelmann, B., Merville, P., Grenier, N., Joly, D., … Canaud, G. (2018).\nTargeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature, 558(7711),\n540–546. https://doi.org/10.1038/s41586-018-0217-9\nProgram Prior Authorization/Medical Necessity- Vijoice® (alpelisib)\nChange Control\n6/2022 New program.\n6/2023 Annual review. Updated references.\n6/2024 Annual review. Revised criteria for presumptive PROS if unable to\nconfirm PIK3CA gene mutation. Updated initial authorization to 12\nmonths. Updated references.\n6/2025 Annual review without changes to coverage criteria.\n© 2025 UnitedHealthcare Services Inc.\n3"
  ]
}